Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.

You may also be interested in...



Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion

Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.

Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion

Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.

Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel